Aptose Picks Up Hanmi’s MKI To Buoy Hematological Cancer Pipeline
$420m Deal Follows Positive Data
Executive Summary
Analysts see Hanmi’s clinical-stage asset as fitting well into Aptose's pipeline and providing potential combination therapy benefits for hematological malignancies.
You may also be interested in...
Deal Watch: Novo Nordisk Links With Flagship To Create Cardiometabolic, Rare Disease Portfolio
The Danish diabetes titan teams with Moderna’s founder on cardiometabolic R&D. Troubled cell therapy biotech Bone Therapeutics negotiates reverse merger with Medsenic.
Korea 2021 Roundup: License Deals, Overseas Sales Key Factors In Earnings
A Scrip roundup of 2021 earnings for major Korean pharma firms shows top performers included Hanmi Pharma, GC Pharma and SK Group affiliates, which were boosted by new license deals, strong overseas sales and high-margin vaccines and other products.
Korean Biopharmas Set For Another Record Year Of Licensing Deals
Scrip takes a look at South Korea’s out-licensing deal trends for 2021, finding that more big transactions are likely as the year moves towards its close despite a wider global slowing in activity, helped by rising innovative R&D.